Imaging
The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure Ma rk A P et e r z a n , 1 ,2 O l i v e r J Ri d e r 2 a n d L i s a J A n d e r s o n 1 1. Cardiology Clinical Academic Group, St George’s Hospital, London, UK; 2. University of Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital, Oxford, UK
Abstract Cardiovascular imaging is key for the assessment of patients with heart failure. Today, cardiovascular magnetic resonance imaging plays an established role in the assessment of patients with suspected and confirmed heart failure syndromes, in particular identifying aetiology. Its role in informing prognosis and guiding decisions around therapy are evolving. Key strengths include its accuracy; reproducibility; unrestricted field of view; lack of radiation; multiple abilities to characterise myocardial tissue, thrombus and scar; as well as unparalleled assessment of left and right ventricular volumes. T2* has an established role in the assessment and follow-up of iron overload cardiomyopathy and a role for T1 in specific therapies for cardiac amyloid and Anderson–Fabry disease is emerging.
Keywords Cardiovascular magnetic resonance, heart failure, late gadolinium enhancement, delayed enhancement, T1 mapping, T2*, myocarditis, cardiomyopathy, cardio-oncology, prognosis Disclosure: The authors have no conflicts of interest to declare. Received: 19 January 2016 Accepted: 24 June 2016 Citation: Cardiac Failure Review, 2016;2(2):115–22. DOI: 10.15420/cfr.2016.2.2.115 Correspondence: Lisa J Anderson, St George’s Hospital, Blackshaw Road, London SW17 0QT, UK. E: [email protected]
Heart failure (HF) can be defined haemodynamically as any abnormality of cardiac structure or function resulting in a failure to deliver oxygen at a rate adequate for tissue requirements, despite normal filling pressures – or only at the expense of increased filling pressures.1 Around half of patients with HF have reduced left ventricle ejection fraction (LVEF; EF
The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure Ma rk A P et e r z a n , 1 ,2 O l i v e r J Ri d e r 2 a n d L i s a J A n d e r s o n 1 1. Cardiology Clinical Academic Group, St George’s Hospital, London, UK; 2. University of Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital, Oxford, UK
Abstract Cardiovascular imaging is key for the assessment of patients with heart failure. Today, cardiovascular magnetic resonance imaging plays an established role in the assessment of patients with suspected and confirmed heart failure syndromes, in particular identifying aetiology. Its role in informing prognosis and guiding decisions around therapy are evolving. Key strengths include its accuracy; reproducibility; unrestricted field of view; lack of radiation; multiple abilities to characterise myocardial tissue, thrombus and scar; as well as unparalleled assessment of left and right ventricular volumes. T2* has an established role in the assessment and follow-up of iron overload cardiomyopathy and a role for T1 in specific therapies for cardiac amyloid and Anderson–Fabry disease is emerging.
Keywords Cardiovascular magnetic resonance, heart failure, late gadolinium enhancement, delayed enhancement, T1 mapping, T2*, myocarditis, cardiomyopathy, cardio-oncology, prognosis Disclosure: The authors have no conflicts of interest to declare. Received: 19 January 2016 Accepted: 24 June 2016 Citation: Cardiac Failure Review, 2016;2(2):115–22. DOI: 10.15420/cfr.2016.2.2.115 Correspondence: Lisa J Anderson, St George’s Hospital, Blackshaw Road, London SW17 0QT, UK. E: [email protected]
Heart failure (HF) can be defined haemodynamically as any abnormality of cardiac structure or function resulting in a failure to deliver oxygen at a rate adequate for tissue requirements, despite normal filling pressures – or only at the expense of increased filling pressures.1 Around half of patients with HF have reduced left ventricle ejection fraction (LVEF; EF
